Pfenex to Announce Second Quarter 2019 Financial Results on August 8
July 25 2019 - 4:10PM
Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and
licensing biotechnology company focused on leveraging its Pfēnex
Expression Technology® to improve protein therapies for unmet
patient needs, today announced that it will report its financial
results for the second quarter and six months ended June 30, 2019,
after the market close on Thursday, August 8, 2019, and will host a
conference call and webcast at 4:30 PM Eastern Time.
|
|
Conference Call & Webcast |
Thursday, August 8th @ 4:30pm Eastern
Time/1:30pm Pacific Time |
Domestic: |
866-376-8058 |
International: |
412-542-4131 |
Webcast: |
https://www.webcaster4.com/Webcast/Page/1061/31219 |
|
|
Replays, Available Through August 15th: |
Domestic: |
877-344-7529 |
International: |
412-317-0088 |
Replay Access Code: |
10133889 |
|
|
About Pfenex Inc.Pfenex is a clinical-stage
development and licensing biotechnology company focused on
leveraging its Pfēnex Expression Technology® to develop and improve
protein therapies for unmet patient needs. Using the patented
Pfēnex Expression Technology platform, Pfenex has created an
advanced pipeline of therapeutic equivalents, vaccines, biologics
and biosimilars. Pfenex also uses its Pfēnex Expression Technology
platform to produce CRM197, a diphtheria toxoid carrier protein
used in prophylactic and therapeutic vaccines. Pfenex’s lead
product candidate is PF708, a therapeutic equivalent candidate to
Forteo® (teriparatide) for the treatment of osteoporosis. In
addition, Pfenex is developing hematology/oncology products,
including PF743, a recombinant crisantaspase, and PF745, a
recombinant crisantaspase with half-life extension technology, in
collaboration with Jazz Pharmaceuticals.
Pfenex investors and others should note that Pfenex announces
material information to the public about Pfenex through a variety
of means, including its website (http://www.pfenex.com/), its
investor relations website (http://pfenex.investorroom.com/), press
releases, SEC filings, public conference calls, corporate Twitter
account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company Contact: Susan A. KnudsonChief
Financial Officer(858) 352-4324sknudson@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2023 to Apr 2024